AMRX
Amneal Pharmaceuticals, Inc.
19.70$
-3.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Amneal Pharmaceuticals, Inc. (AMRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -19 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36 | 69 | 26 | 74 | 65 | 27 | -99 | 62 | 260 | -108 | 21 | 140 | -51 | 49 | 179 | 45 | 106 | 148 | -52 | 82 | 63 | 76 | -126 | 94 | -23 | 140 | -11 | 81 | 136 | -4.4 | 40 | 142 | 118 | 7.4 | 84 | 118 | 130 | -29 | -19 | 201 | |
| 9.7 | 11 | 11 | 12 | 13 | 15 | 32 | 43 | 47 | 49 | 51 | 53 | 54 | 58 | 58 | 62 | 62 | 56 | 56 | 60 | 64 | 58 | 60 | 64 | 63 | 58 | 57 | 57 | 57 | 56 | 63 | 59 | 66 | 60 | 60 | 54 | 49 | 43 | 48 | 194 | |
| – | – | – | 34 | -0.5 | 1.6 | 160 | 3.6 | 3.6 | 4.3 | 6.2 | 6.1 | 5.0 | 4.5 | 5.7 | 5.4 | 5.1 | 5.3 | 7.6 | 7.7 | 7.7 | 8.1 | 8.3 | 7.7 | 7.8 | 7.6 | 6.6 | 6.7 | 6.0 | 6.7 | 6.7 | 7.1 | 7.2 | 7.3 | 8.3 | 8.2 | 8.2 | 8.8 | 10 | 36 | |
| 29 | -13 | -14 | – | 17 | -9.3 | 197 | 29 | 75 | 85 | 29 | 510 | 31 | 29 | 24 | 52 | 23 | 21 | 39 | 26 | 47 | 16 | -86 | 27 | 55 | 35 | 20 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -67 | 23 | -5.8 | -2.3 | -19 | -31 | -88 | -29 | 156 | -155 | -11 | 121 | -74 | -162 | 118 | -163 | 50 | 55 | -164 | -2.4 | -11 | 51 | 19 | 114 | -79 | 54 | -120 | -35 | 54 | -12 | -117 | 43 | 22 | -106 | -35 | -51 | -12 | -190 | -192 | -445 | |
| 31 | 25 | 30 | 35 | 25 | 19 | 20 | 37 | 20 | 18 | 62 | 13 | 4.8 | 8.4 | 8.6 | 15 | 31 | 12 | 7.8 | 11 | 18 | 11 | 17 | 18 | 11 | 12 | 12 | 13 | 32 | 20 | 11 | 21 | 23 | 18 | 27 | 15 | 43 | 14 | 46 | 118 | |
| -36 | -25 | -30 | -35 | -8.9 | -19 | -341 | -41 | 5.3 | -21 | -23 | 30 | -4.8 | -262 | -8.9 | -15 | -32 | -13 | -83 | -12 | -87 | -97 | -16 | -49 | -11 | -12 | -12 | -13 | -32 | -20 | -6.5 | -21 | -16 | -18 | -27 | -22 | -45 | -22 | -123 | -212 | |
| 30 | 20 | 295 | 60 | 20 | 30 | 153 | 0.0 | 183 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | – | – | 0.0 | 0.0 | 2.3 | -11 | 155 | 1.0 | -0.9 | 0.0 | 0.0 | -0.5 | -0.1 | -0.2 | -0.1 | -2.1 | -0.3 | -0.2 | -0.1 | -3.0 | -0.3 | -0.2 | -0.1 | -2.0 | 0.0 | -0.2 | 2.0 | -7.2 | -0.2 | -0.2 | -0.4 | -22 | -0.2 | – | – | – | – | – | |
| 22 | -28 | 296 | – | 286 | -3.6 | 577 | 93 | -184 | -6.8 | -6.8 | -6.8 | -6.8 | 476 | -300 | -9.7 | -9.7 | -1.0 | -10 | -34 | -9.8 | -9.8 | 32 | -43 | -18 | 80 | 20 | – | – | – | – | -87 | -56 | -18 | -16 | 140 | -6.1 | -6.2 | 94 | 222 | |
| -9.0 | -28 | -3.8 | -64 | 0.5 | -33 | 457 | 83 | -219 | -22 | -9.1 | -7.6 | -7.3 | 468 | -310 | -15 | -11 | -26 | -38 | -44 | -30 | -18 | 23 | -46 | -22 | -13 | -12 | -87 | -101 | -23 | -35 | -92 | -61 | -39 | -42 | 59 | -10 | -57 | 77 | 70 | |
| -9.4 | 28 | -3.5 | -30 | 57 | -25 | 16 | 104 | 47 | -152 | -9.7 | 160 | -64 | 254 | -139 | 15 | 63 | 109 | -173 | 27 | -54 | -40 | -118 | -2.3 | -61 | 116 | -36 | -19 | 3.5 | -47 | -2.0 | 29 | 40 | -50 | 15 | 155 | 75 | -109 | -66 | 55 | |
| 5.2 | 45 | -3.9 | 38 | 41 | 7.5 | -119 | 25 | 240 | -126 | -41 | 127 | -56 | 41 | 171 | 30 | 75 | 136 | -60 | 72 | 45 | 66 | -143 | 76 | -35 | 128 | -24 | 68 | 104 | -24 | 29 | 121 | 95 | -11 | 57 | 103 | 87 | -43 | -65 | 83 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.